Placebo (n = 140) | Auxora (n = 141) | |
---|---|---|
Discontinuation due to AEs, n (%) | 5 (3.6%) | 3 (2.1%) |
Serious adverse events ≥ 4%, n (%) | ||
Respiratory failure | 26 (18.6%) | 22 (15.6%) |
ARDS | 11 (7.9%) | 7 (5.0%) |
Pneumonia | 7 (5.0%) | 6 (4.3%) |
Cardiac arrest | 6 (4.3%) | 6 (4.3%) |
Septic shock | 8 (5.7%) | 2 (1.4%) |
Most common treatment-emergent adverse events ≥ 4%, n (%) | ||
Respiratory failure | 26 (18.6%) | 22 (15.6%) |
Blood triglycerides increased | 5 (3.6%) | 16 (11.3%) |
Hypertriglyceridemia | 4 (2.9%) | 2 (1.4%) |
Hyperglycemia | 11 (7.9%) | 11 (7.8%) |
Acute kidney injury | 16 (11.4%) | 10 (7.1%) |
Increased transaminases | 5 (3.6%) | 8 (5.7%) |
Liver function test increased | 1 (0.7%) | 5 (3.5%) |
ARDS | 11 (7.9%) | 7 (5.0%) |
DVT | 7 (5.0%) | 7 (5.0%) |
Pneumonia | 7 (5.0%) | 7 (5.0%) |
Pneumothorax | 6 (4.3%) | 7 (5.0%) |
Pneumomediastinum | 2 (1.4%) | 6 (4.3%) |
Hypoxia | 7 (5.0%) | 6 (4.3%) |
Cardiac arrest | 6 (4.3%) | 6 (4.3%) |
Hyperkalemia | 6 (4.3%) | 4 (2.8%) |
Anemia | 9 (6.4%) | 3 (2.1%) |
Septic Shock | 13 (9.3%) | 2 (1.4%) |